CDKL5 deficiency disorder (CDD): cross-border specialty drug access for international patients

Quick orientation

CDKL5 deficiency disorder is estimated to affect 1 in 40,000 to 60,000 live births. It is one of the most common genetic causes of early-onset, treatment-resistant epilepsy.

Typical age of onset. Seizures typically begin within the first 3 months of life. Diagnosis follows genetic testing.

Severity tiers. Most affected children have severe developmental delay, refractory epilepsy, motor impairment, and visual processing differences. Severity varies but the disorder is uniformly disabling.

Why specialty drugs for CDKL5 deficiency disorder (CDD) are hard to access internationally

Ztalmy (ganaxolone) is the first FDA-approved therapy specifically labeled for CDKL5-related seizures (2022). It is not registered in most MENA and South Asian markets, and the oral suspension format requires consistent supply for pediatric titration. Most international families end up on standard antiseizure regimens that are not specifically indicated for CDD.

Treatments approved by the FDA

• Ztalmy (ganaxolone) — FDA approval: 2022. Mechanism: Positive allosteric modulator of GABA-A receptors. Route: Oral suspension three times daily. US WAC ballpark: Approximately USD 90,000 to 130,000 per year, weight-based. Country pricing: Saudi Arabia · Qatar · Egypt · Jordan · Lebanon.

Cross-border pathways used for CDKL5 deficiency disorder (CDD)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Rare Pediatric Disease

What your physician needs to know

• Confirm pathogenic CDKL5 variant by genetic testing.
• Document seizure types, frequency, and prior antiseizure medications.
• Weight-based dosing requires updated pediatric weight at each refill.
• Coordinate with a pediatric epileptologist familiar with developmental and epileptic encephalopathies.
• Document failure of standard antiseizure regimens before requesting Ztalmy.

Common questions

Is Ztalmy approved outside the United States?

It is approved in the EU and a small number of other markets. In most MENA and South Asian countries it is not yet registered.

Can a child under age 2 receive Ztalmy?

The FDA label is for patients aged 2 years and older. Some compassionate-use requests have considered earlier initiation case by case.

How is the suspension shipped internationally?

Standard temperature-controlled shipping; specific storage conditions are confirmed at order.

Will it replace other antiseizure medications?

Generally not. Ztalmy is added on to existing regimens in most cases. Your epileptologist decides.

What documents are required?

Genetic confirmation, treating physician prescription, recent clinical summary including a seizure diary.

How long is supply continuity?

Reserve Meds plans for 3-month rolling supply with refill triggers, subject to destination-country quantity limits.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For CDKL5 deficiency disorder (CDD), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for CDKL5 deficiency disorder (CDD)

Reserved for you.